Ingredient Dossier · 5-Brain® Formula · nutropx.com/science
Meriva® Curcumin
The Bioavailable Phytosome — Curcumin’s Absorption Problem, Solved
Curcumin — the principal bioactive compound in turmeric (Curcuma longa) — has been studied extensively for its associations with brain health, BDNF, and antioxidant defense. The problem: standard curcumin is notoriously poorly absorbed by the body. Meriva® is Indena’s patented phytosome technology that addresses this absorption challenge through a phospholipid complex — supported by a single peer-reviewed Meriva-specific human pharmacokinetic finding of approximately 29-fold improved curcuminoid absorption.
~29× better curcuminoid absorption
Patented Indena phytosome technology
Standardized to 18–20% curcuminoids
Curcuma longa root extract
Branded: Indena S.p.A.
Meriva®by Indena S.p.A.
Phytosome technology
Patented complex
~29× absorption (Cuomo 2011)
No piperine required
GRAS-affirmed curcumin source
The Meriva-specific anchor finding
~29×
Higher total curcuminoid absorption than the corresponding unformulated curcuminoid mixture — measured by area-under-the-curve plasma concentration in a randomized double-blind crossover pharmacokinetic study.
Source: Cuomo J, Appendino G, Dern AS, et al. Comparative Absorption of a Standardized Curcuminoid Mixture and Its Lecithin Formulation. Journal of Natural Products. 2011;74(4):664–669. n=9 healthy adults. PMID 21413691. DOI 10.1021/np1007262.
Curcumin isolated
1815
Vogel & Pelletier identification
Meriva developed
2000s
Indena phytosome technology
5-Brain® dose
150 mg
Per 3-capsule daily serving
Curcuminoid content
18–20%
Standardized by HPLC
01
What is it?
Curcumin is the principal yellow-pigmented bioactive compound in turmeric (Curcuma longa), a rhizome used as both a culinary spice and a medicinal botanical in Ayurvedic and Traditional Chinese Medicine for thousands of years. Modern research has documented curcumin’s mechanistic activity in pathways relevant to brain health — including BDNF (brain-derived neurotrophic factor) support, Nrf2-mediated antioxidant activity, and modulation of inflammatory signaling.
The challenge: standard curcumin is notoriously poorly absorbed. Its low water solubility, chemical instability in the gut, and rapid metabolism mean that very little of an oral dose reaches systemic circulation. This is the central problem that bioavailability-enhanced curcumin formulations aim to solve.
Meriva® is Indena S.p.A.’s patented solution: a phytosome complex in which curcumin extract is complexed with phosphatidylcholine — a phospholipid — to form a lipid-compatible molecular structure that improves absorption through the intestinal wall. The result, demonstrated in Cuomo et al. (2011), is approximately 29-fold higher total curcuminoid absorption than unformulated curcumin in human plasma.
Important formulation note: Meriva® is a curcumin–phosphatidylcholine complex, not phosphatidylserine. The two phospholipids are different molecules with different roles. 5-Brain® separately contains Sharp-PS® Green phosphatidylserine as a distinct ingredient with a separate purpose — do not conflate the two.
02
Research timeline
~4,000 BCE
Traditional use of turmeric — Documented across Ayurvedic and Traditional Chinese Medicine systems for thousands of years as both culinary spice and medicinal botanical.
1815
Curcumin chemically isolated — Vogel and Pelletier identify and isolate the yellow pigment compound from turmeric, naming it curcumin. Its structural characterization continues into the 20th century.
1970s–1990s
Modern pharmacological research era — Curcumin’s pharmacology is characterized in detail — antioxidant activity, NF-κB modulation, anti-microbial properties. The persistent problem identified across studies: extremely poor oral bioavailability.
1998
Shoba piperine bioavailability study — Demonstrates that combining curcumin with piperine (black pepper extract) increases curcumin bioavailability ~20-fold. This becomes the popular but imperfect early solution. Higher-bioavailability technologies follow.
2000s
Meriva® phytosome developed — Indena S.p.A. develops the curcumin–phosphatidylcholine phytosome complex. Uses no piperine; instead leverages phospholipid complexation for absorption support.
2011
Cuomo et al. (J Nat Prod) — the Meriva-specific anchor study — Randomized double-blind crossover pharmacokinetic study in 9 healthy adults. Total curcuminoid absorption approximately 29-fold higher for Meriva vs unformulated curcumin. The single peer-reviewed Meriva-specific human finding directly supporting the brand’s absorption claim.
2012–2020
Bioavailable curcumin cognition research era — A series of RCTs investigates bioavailable curcumin formulations (Longvida, Theracurmin, HydroCurc) in healthy and aging adults for cognition, mood, antioxidant defense, and BDNF support. These studies use other formulations, not Meriva specifically.
2019
Sarraf et al. (Nutrition Research) BDNF meta-analysis — Systematic review and meta-analysis of curcumin RCTs (4 trials, n=139) finds curcumin supplementation was associated with significantly increased serum BDNF (mixed formulations, mixed populations).
03
How it works — mechanisms of action
Curcumin’s mechanistic profile is exceptionally well-characterized at the cellular and molecular level. Three pathways are most relevant to brain health and the 5-Brain® framework: BDNF support, Nrf2-mediated antioxidant activity, and modulation of healthy inflammatory response signaling.
Meriva® phytosome — curcumin complexed with phosphatidylcholine
Meriva® is a patented phytosome formulation in which curcuminoids are complexed with phosphatidylcholine (a phospholipid abundant in cell membranes). This lipid environment improves passage through the intestinal barrier. The 29× figure is from the Cuomo 2011 head-to-head pharmacokinetic study.
Curcuminoid molecules
Phosphatidylcholine (lipid carrier)
Intestinal barrier
Professor 5-Brain explains
Here’s the puzzle that makes Meriva interesting: regular curcumin has a long list of fascinating activities in the lab — but your gut barely lets any of it through. It’s like having a great supplement that gets lost in the mail. Meriva wraps curcumin in a phospholipid (basically the same kind of fat your cell membranes are made of), which helps it slip through the intestinal wall much more efficiently. The ~29-fold absorption finding is the one piece of human evidence that’s directly Meriva-specific. Everything else — BDNF, antioxidant defense, balanced inflammatory response — is curcumin’s mechanistic story at the category level.
Phytosome bioavailability technology
Curcumin is non-covalently complexed with phosphatidylcholine — a phospholipid — creating a lipid-compatible structure that improves absorption across the intestinal wall. The Meriva-specific human finding documents approximately 29-fold higher total curcuminoid absorption vs unformulated curcumin (Cuomo 2011).
Meriva-specific human PK evidence
BDNF (brain-derived neurotrophic factor) support
Curcumin is studied for associations with the CREB–BDNF signaling pathway, including modulation of cAMP and ERK/p38 MAPK activity. Human evidence: Sarraf 2019 meta-analysis associates curcumin supplementation with raised serum BDNF; Tiekou Lorinczova 2020 reported serum BDNF was 35% higher with iron + curcumin vs iron + placebo. Mechanism studied at the curcumin category level, not Meriva-specifically.
Human evidence — mixed formulations, not Meriva-specific
Antioxidant defense & Nrf2 pathway
Curcumin scavenges reactive oxygen species directly and is studied for activation of the Nrf2/ARE transcriptional pathway, supporting endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione systems). DiSilvestro 2012 reported raised salivary radical-scavenging capacity and plasma catalase activity with bioavailable curcumin.
Well-established mechanism · Human evidence (other curcumin formulations)
Healthy inflammatory response signaling
Curcumin is studied for modulation of NF-κB signaling and downstream cytokine pathways. As a structure/function ingredient, this is framed as supporting a healthy, balanced inflammatory response — a normal biological process — not as a disease intervention.
Supporting mechanism research
Neuronal signaling & resilience
Preclinical and mechanistic research suggests curcumin may modulate serotonin and dopamine signaling and support neuronal resilience under cellular stress. These are mechanism-level findings, largely from animal and cell research, and do not translate to mood-disorder or neuroprotection claims.
Preclinical research · Mechanism characterization
Phosphatidylcholine carrier role
The phosphatidylcholine in the Meriva complex is itself a major neuronal membrane phospholipid and a choline source. While its primary role in Meriva is delivery, the carrier component is biochemically relevant to membrane health.
Biochemical context · Carrier function established
04
5-Brain® system mapping
Meriva®’s 5-Brain® associations are anchored in well-characterized curcumin mechanisms, with the explicit caveat that the cognitive and BDNF evidence cited reflects bioavailable curcumin as a category rather than Meriva-specifically.
Brain Energy & Longevity
Primary association. Curcumin is well-studied for Nrf2-mediated antioxidant defense and BDNF-related neuronal resilience — mechanisms relevant to long-term brain cell health and oxidative defense.
Memory & Learning
Studied via the BDNF mechanism, central to synaptic plasticity and learning. Sarraf 2019 meta-analysis associates curcumin with serum BDNF in healthy adults. Mechanism category, not Meriva-specific.
Mood & Stress Resilience
Bioavailable curcumin studied for associations with calm and contentedness in healthy older adults (Cox 2015, 2020 — using Longvida, not Meriva). Studied in the context of a healthy inflammatory environment.
Focus & Attention
Bioavailable curcumin (Longvida) associated with sustained attention and working memory in Cox 2015. Indirect at Meriva and 5-Brain dose levels.
Neural Communication
Indirect via phosphatidylcholine carrier and serotonin/dopamine modulation. Not the primary studied domain for curcumin.
05
Research evidence — full context
Each study below explicitly states the curcumin formulation used. Meriva-specific data is limited to the bioavailability finding (Cuomo 2011). The cognition and BDNF data comes from other bioavailable curcumin formulations (Theracurmin, Longvida, HydroCurc) and supports the curcumin category, not Meriva-specifically.
Cuomo et al. (2011) — Journal of Natural Products
n=9 healthy adults · Meriva 209–376 mg curcuminoids vs unformulated curcumin 1,799 mg · Single-dose crossover PK
The single Meriva-specific peer-reviewed human study. Researchers reported total curcuminoid absorption approximately 29-fold higher for Meriva than for the corresponding unformulated curcuminoid mixture. Phospholipid complexation supported absorption of demethoxylated curcuminoids more than parent curcumin. Authors’ explicit caveat: only phase-2 metabolites were detected in plasma, and plasma concentrations remained significantly lower than levels typically required for inhibition of curcumin’s laboratory targets at the cellular level. Small sample (n=9) is a limitation.
Key takeawayThe Meriva-specific anchor study. Cuomo et al. 2011 directly compared Meriva to unformulated curcuminoid mixture in healthy volunteers (n=9 crossover) and reported approximately 29× higher total curcuminoid absorption for Meriva. The single most important head-to-head evidence for the formulation.
Small et al. (2018) — Am J Geriatric Psychiatry
n=40 non-demented adults 51–84 yrs · Theracurmin 180 mg curcumin/day · 18 months · Includes FDDNP-PET imaging
Researchers reported that bioavailable curcumin was associated with verbal memory (effect size 0.63, p=0.002), visual memory (ES 0.50–0.51), and attention (ES 0.96, p<0.0001) over 18 months in non-demented older adults. Formulation: Theracurmin (colloidal nanoparticle dispersion) — not Meriva. Provides bioavailable-curcumin category evidence rather than Meriva-specific evidence. The FDDNP-PET amyloid/tau imaging substudy is mechanistic science investigating biomarkers of cognitive change.
Key takeawayCognitive performance study using Theracurmin — a different bioavailable curcumin formulation than Meriva. Results cannot be directly transferred. Cited for context on the curcumin-cognition research direction; not direct Meriva evidence.
Cox et al. (2015) — J Psychopharmacology
n=60 healthy adults 60–85 yrs · Longvida 400 mg/day (~80 mg curcumin) · 4 weeks · Acute & chronic assessments
One hour after a single dose, researchers reported bioavailable curcumin was associated with sustained attention and working memory measures vs placebo. After 4 weeks of daily use, associations with working memory and mood measures (lower fatigue, better calmness and contentedness under psychological stress) were reported. Formulation: Longvida (solid lipid curcumin particle) — not Meriva. Dose is ~3× the 5-Brain Meriva curcuminoid content.
Key takeawayMemory study using Longvida — another curcumin formulation, not Meriva. Different absorption profile and bioactive distribution. Cited for the broader category research only.
Cox et al. (2020) — Nutrients
n=80 adults 50–80 yrs · Longvida 400 mg/day · 12 weeks
Researchers reported that bioavailable curcumin was associated with better working memory at 12 weeks (Serial Threes, Serial Sevens, virtual Morris Water Maze) and lower POMS fatigue scores at 4 and 12 weeks. Honest caveat: the curcumin group also had significantly elevated blood glucose — a flagged finding that authors disclosed transparently. Formulation: Longvida — not Meriva.
Key takeawayBDNF study with HydroCurc formulation in healthy adults. Provides mechanism support for curcumin’s BDNF-related activity at the species level, but used a different formulation than Meriva.
Tiekou Lorinczova et al. (2020) — Antioxidants
n=155 healthy adults (mean age ~26) · HydroCurc 500 mg/day ± iron · 6 weeks · 5 arms
First human demonstration that adding curcumin (vs iron alone) was associated with raised serum BDNF. Researchers reported serum BDNF was 26% higher in the curcumin + low-iron group from baseline, and 35% higher than the iron + placebo group at endpoint. Important caveat: the BDNF association was tied to the iron + curcumin combination, not curcumin alone. Formulation: HydroCurc — not Meriva.
Key takeawayTheracurmin in healthy adults with subjective memory complaints. Different formulation from Meriva; provides context for the curcumin-cognition research direction.
Sarraf et al. (2019) — Nutrition Research
Meta-analysis: 4 RCTs, pooled n=139 · Mixed curcumin formulations · Doses 200–1,820 mg/day · 8–12 weeks
Pooled analysis associated curcumin supplementation with significantly increased serum BDNF (weighted mean difference 1,789 pg/mL; 95% CI 722–2,857; p<0.01). High heterogeneity noted (I²=83.5%). Caveats: mixed formulations (not Meriva-specific), small pooled sample, several included trials in disease (not healthy) populations. Provides category-level support for the BDNF mechanism in curcumin research.
Key takeawayAnimal mechanism study for BDNF and neurogenesis. Preclinical evidence supporting the mechanism narrative; not direct human outcome evidence.
DiSilvestro et al. (2012) — Nutrition Journal
n=38 healthy middle-aged adults 40–60 yrs · Longvida 80 mg/day · 4 weeks
Researchers reported bioavailable curcumin was associated with raised salivary radical-scavenging capacity, raised plasma catalase activity, and increased plasma nitric oxide — consistent with Nrf2-mediated antioxidant support. Notably, this study used the dose closest to 5-Brain’s curcuminoid content (80 mg Longvida ~ 16–20 mg curcumin). Formulation: Longvida — not Meriva. Small sample, short duration.
Key takeawayCurcumin and inflammatory response pathways (NF-κB, COX-2). Preclinical/cell-culture mechanism evidence; supports the inflammatory-response narrative at the molecular level only.
Belcaro et al. (2010) & Allegri et al. (2010) — Tolerability data
Belcaro: n=50 (3 mo) and n=100 (8 mo) at 1,000 mg/day Meriva · Allegri: n=106 (12 mo) at 1,200 mg/day Meriva
In long-term registry studies of Meriva at 1,000–1,200 mg/day (far above 5-Brain®’s 150 mg), the ingredient was reported well tolerated, with a single dropout for gastric intolerance in the Allegri 12-month study. These studies were conducted in populations with diagnosed conditions (osteoarthritis, uveitis), and the relevance here is for tolerability and safety at extended-duration high doses — not for cognitive efficacy.
Key takeawayBelcaro and Allegri Meriva clinical trials in osteoarthritis joint comfort populations. These are not cognitive trials — included to show Meriva-specific clinical research exists, but in joint health context, not cognition. We do not transfer findings to brain claims.
06
What the research actually says
Honest evidence summary
Meriva® is one of the most rigorously characterized bioavailability-enhanced curcumin technologies in the supplement market — but the depth of the Meriva-specific evidence is concentrated in one specific area: absorption. The cognitive and BDNF evidence comes from other curcumin formulations, which is a critical distinction.
What studies consistently support
- Cuomo et al. 2011 demonstrated approximately 29× higher total curcuminoid absorption for Meriva vs unformulated curcuminoid mixture in a head-to-head pharmacokinetic study (n=9 healthy volunteers, randomized crossover). This is the Meriva-specific anchor finding.
- Curcumin’s mechanism profile (BDNF, Nrf2 antioxidant pathway, NF-κB and inflammatory response modulation) is exceptionally well-characterized at the cellular and molecular level across the broader curcumin literature.
- Meriva has a long-term tolerability record at high doses (1,000–1,200 mg/day) in extended-duration registry studies (Belcaro 2010; Allegri 2010), supporting safety confidence.
- Multiple other bioavailable curcumin formulations (Theracurmin, Longvida, HydroCurc) have shown cognitive and BDNF associations in healthy adults — supporting the category-level mechanism direction.
What remains uncertain
- Whether Meriva specifically produces cognitive effects in humans. No published Meriva-specific cognitive or BDNF outcome study exists. The cognitive curcumin evidence used Theracurmin, Longvida, HydroCurc — different formulations than Meriva.
- Whether 5-Brain®’s 150 mg dose (~27–30 mg curcuminoids) produces effects comparable to the 80–180+ mg curcumin doses in other-formulation cognitive trials. The 29× absorption advantage narrows the dose gap but doesn’t eliminate it.
- Whether Meriva’s phosphatidylcholine carrier contributes additional brain effects beyond the curcumin payload. Phosphatidylcholine is a brain cell membrane component, but a contribution from the carrier specifically has not been studied.
- Whether the BDNF mechanism demonstrated in animal studies translates to measurable human cognitive outcomes at supplement doses.
What to realistically expect
- Meriva is positioned in 5-Brain® as a highly bioavailable curcumin source — the 29× absorption advantage is a real, head-to-head differentiator from generic curcumin.
- The contribution is best understood as supporting the BDNF and antioxidant mechanism dimensions of the multi-ingredient formula, not as a standalone cognitive driver.
- Do not expect Meriva to function like the cognitive Theracurmin or Longvida trial outcomes at our dose — different formulations, different doses, different study designs.
- The long-term tolerability record at high doses provides safety confidence at the 5-Brain® serving (a fraction of registry-study doses).
Professor 5-Brain — the honest take
Meriva is the ingredient in 5-Brain® where the marketing temptations are biggest, and we’ve worked hardest to resist them. The 29× absorption finding is real and head-to-head verified — that part we’ll defend. But the cognitive trials? Those used Theracurmin, Longvida, HydroCurc — not Meriva. Saying “Meriva improves cognition” would be a formulation-transfer fallacy, and we don’t do that here. What we will say: Meriva is a bioavailable, well-tolerated, brain-relevant curcumin source contributing curcumin’s mechanism profile to the 5-Brain® formula in a defensible way.
07
Why we selected Meriva®
Formulation rationale
The absorption advantage is the central problem worth solving. Standard curcumin is poorly absorbed by the human gut — this is the consensus finding across decades of pharmacokinetic research. Including unformulated curcumin in a brain supplement would deliver minimal systemic exposure regardless of dose. Meriva®’s ~29-fold absorption advantage (Cuomo 2011) is the rationale for using it specifically.
Phytosome, not piperine. Many curcumin supplements use black pepper extract (piperine) to enhance absorption. Piperine works, but it also affects drug metabolism and may amplify any hepatotoxicity risk from curcumin itself. Meriva® uses phospholipid complexation instead — achieving comparable or superior absorption without piperine and its drug-interaction profile.
Backed by Indena’s phytomedicine research history. Indena S.p.A. is one of the most established phytomedicine ingredient suppliers globally and has published the Meriva phytosome technology in peer-reviewed pharmacology journals. The Meriva tolerability data — including long-term 8–12 month registries at 1,000–1,200 mg/day — provides confidence in the ingredient’s safety profile at doses far exceeding 5-Brain’s 150 mg.
Complementary mechanism profile. No other ingredient in the 5-Brain® formula addresses Nrf2-mediated antioxidant defense or BDNF support through the curcumin pathway. Meriva fills these specific mechanistic dimensions, contributing antioxidant defense and the inflammatory-response-balance dimension to the multi-ingredient stack.
08
Synergy within the 5-Brain® formula
Meriva® + Sharp-PS® Green
Meriva® is studied for the inflammatory environment around neurons; Sharp-PS® Green is studied for the structural integrity of neuronal membranes themselves. Different aspects of neuronal membrane support — chemical environment and structural composition.
Environment + Structure
Meriva® + Bacopa
Both ingredients have studied associations with BDNF-related neuroplasticity pathways — Bacopa via bacoside-mediated synaptic mechanisms, curcumin via the CREB–BDNF axis. Convergent mechanisms approaching the same pathway from different molecular angles.
Convergent BDNF support
Meriva® + ALCAR
Curcumin is studied for Nrf2-mediated antioxidant activity in brain tissue; ALCAR for mitochondrial energy support. Both have studied associations with the cellular environment around neuronal mitochondria, addressing different dimensions of cellular bioenergetics and oxidative defense.
Antioxidant + Energy metabolism
Meriva® + Ginkgo
Both ingredients have studied associations with antioxidant and healthy inflammatory response pathways relevant to brain health. Complementary oxidative defense mechanisms through different molecular targets (flavone glycosides vs curcuminoids).
Dual antioxidant pathways
09
Dosage & context
5-Brain® dose
150 mg
per day · Meriva® phytosome · ~27–30 mg curcuminoids
Most positive bioavailable curcumin cognition trials used 80–180 mg curcumin/day from various branded forms — 5-Brain’s dose is a foundational, daily-maintenance level within a multi-ingredient formula
Meriva’s ~29× absorption advantage (Cuomo 2011) means a lower nominal dose can support meaningful plasma exposure compared to unformulated curcumin
Take with a meal containing dietary fat — curcuminoids are fat-soluble and the phytosome complex is lipid-compatible
Discontinue at least 2 weeks before any planned surgical procedure — per DaVinci Laboratories guidance for the 5-Brain® formula
10
Safety & tolerability
Turmeric/curcumin liver-injury safety note (important): A documented signal of rare, idiosyncratic liver injury has been associated with turmeric and curcumin products — particularly enhanced-bioavailability formulations and products containing piperine. The NIH LiverTox monograph and a 2023 Drug-Induced Liver Injury Network (DILIN) case series describe cases predominantly in individuals carrying the HLA-B*35:01 allele. Meriva® uses phospholipid complexation, not piperine, for absorption, and 5-Brain®’s 150 mg dose is far below the doses associated with case reports. If you have a history of liver disease, take hepatotoxic medications, or experience symptoms such as jaundice, dark urine, persistent nausea, fatigue, or right-upper-quadrant pain, discontinue use and consult your healthcare provider promptly.
Established tolerability
- Meriva® well tolerated in long-term studies at 1,000–1,200 mg/day for 8–12 months (Belcaro 2010, Allegri 2010)
- 5-Brain® dose (150 mg) is far below studied long-term doses
- Curcumin GRAS-affirmed; JECFA Acceptable Daily Intake 0–3 mg/kg body weight/day
- No piperine in Meriva® — avoids drug-metabolism interactions from black pepper extract
- Mild GI effects (transient nausea, soft stool) reported in a subset of users at higher doses
Important cautions
- History of liver disease or hepatotoxic medication use — consult your healthcare provider before use
- Discontinue and seek medical attention if symptoms of liver trouble develop (jaundice, dark urine, persistent fatigue, right-upper-quadrant pain)
- Gallbladder disease or bile-duct obstruction — curcumin stimulates gallbladder contraction; avoid in these conditions
- Anticoagulant or antiplatelet medication use (warfarin, aspirin, clopidogrel, NSAIDs) — consult your provider; discontinue 2 weeks before surgery
- Pregnancy or nursing — supplement-level curcumin is not recommended; consult your healthcare provider
- Iron deficiency — curcumin may chelate iron and affect absorption; discuss with your provider
11
Frequently asked questions
What makes Meriva® different from regular curcumin or turmeric?
Two things. First, standard curcumin is notoriously poorly absorbed by the human gut — very little reaches systemic circulation. Meriva® addresses this through phytosome technology: curcumin is complexed with phosphatidylcholine to form a lipid-compatible structure that supports absorption. The Cuomo 2011 pharmacokinetic study reported approximately 29-fold higher total curcuminoid absorption for Meriva vs unformulated curcumin in healthy adults. Second, Meriva uses no piperine (black pepper extract) — an absorption enhancer common in other curcumin products that also affects drug metabolism.
Is Meriva® the same as the phosphatidylserine in 5-Brain®?
No — this is an important distinction. Meriva® is a curcumin–phosphatidylcholine complex. Sharp-PS® Green, a separate ingredient in 5-Brain®, is phosphatidylserine. The two phospholipids have different chemical structures and different roles in the brain. The 5-Brain® formula deliberately includes both for their distinct contributions: Meriva for the bioavailable curcumin delivery, Sharp-PS® Green for the neuronal membrane structural role.
Has Meriva® been studied for brain function or cognitive support?
No published human study has used Meriva® specifically with a validated cognitive or BDNF endpoint. The Meriva-specific human evidence is the Cuomo 2011 pharmacokinetic study showing the ~29-fold absorption advantage. The cognitive and BDNF research on bioavailable curcumin — which supports the underlying mechanisms — has used other formulations (Theracurmin, Longvida, HydroCurc). These studies support the curcumin category and the mechanisms at the scientific-literature level. We are transparent about this distinction throughout this page.
Why is the dose in 5-Brain® lower than clinical trial doses?
5-Brain® delivers 150 mg Meriva per daily serving (approximately 27–30 mg curcuminoids). Most published positive cognitive trials used 80–180 mg of curcumin from other formulations; some used considerably higher doses. The 5-Brain® formula is designed as a multi-ingredient system where Meriva contributes the bioavailable curcumin dimension within a complementary stack of mechanisms. Meriva’s ~29× absorption advantage means a lower nominal dose supports meaningfully higher curcuminoid plasma exposure than the same dose of unformulated curcumin would.
I’ve heard about turmeric and liver concerns. Should I worry?
This is a legitimate and important question. Rare cases of idiosyncratic liver injury have been associated with turmeric and curcumin products — particularly enhanced-bioavailability formulations and those containing piperine, and especially in individuals carrying the HLA-B*35:01 genetic variant (described in the 2023 DILIN case series and the NIH LiverTox monograph). Meriva® uses phospholipid complexation, not piperine, and 5-Brain®’s 150 mg dose is far below the doses involved in case reports. However, if you have a history of liver issues, are taking medications metabolized by the liver, or notice symptoms like jaundice, dark urine, persistent fatigue, or right-upper-quadrant pain, discontinue use and consult your healthcare provider.
References
Cuomo J et al. (2011) J Nat Prod 74(4):664–9 · PMID 21413691 · Small GW et al. (2018) Am J Geriatr Psychiatry 26(3):266–77 · PMID 29246725 · Cox KHM et al. (2015) J Psychopharmacol 29(5):642–51 · PMID 25277322 · Cox KHM et al. (2020) Nutrients 12(6):1678 · PMID 32512782 · DiSilvestro RA et al. (2012) Nutr J 11:79 · PMID 23013352 · Santos-Parker JR et al. (2017) Aging (Albany NY) 9(1):187–208 · PMID 28070018 · Tiekou Lorinczova H et al. (2020) Antioxidants 9(8):645 · PMID 32707771 · Sarraf P et al. (2019) Nutr Res 69:1–8 · PMID 31279955 · Belcaro G et al. (2010) Panminerva Med 52(2 Suppl 1):55–62 · PMID 20657536 · Allegri P et al. (2010) Clin Ophthalmol 4:1201–6 · PMID 21060672 · Halegoua-DeMarzio D et al. (2023) Am J Med 136(2):200–6 · PMID 36252717 (turmeric liver injury) · Shoba G et al. (1998) Planta Med 64(4):353–6 (piperine bioavailability)
Cuomo J et al. (2011) J Nat Prod 74(4):664–9 · PMID 21413691 · Small GW et al. (2018) Am J Geriatr Psychiatry 26(3):266–77 · PMID 29246725 · Cox KHM et al. (2015) J Psychopharmacol 29(5):642–51 · PMID 25277322 · Cox KHM et al. (2020) Nutrients 12(6):1678 · PMID 32512782 · DiSilvestro RA et al. (2012) Nutr J 11:79 · PMID 23013352 · Santos-Parker JR et al. (2017) Aging (Albany NY) 9(1):187–208 · PMID 28070018 · Tiekou Lorinczova H et al. (2020) Antioxidants 9(8):645 · PMID 32707771 · Sarraf P et al. (2019) Nutr Res 69:1–8 · PMID 31279955 · Belcaro G et al. (2010) Panminerva Med 52(2 Suppl 1):55–62 · PMID 20657536 · Allegri P et al. (2010) Clin Ophthalmol 4:1201–6 · PMID 21060672 · Halegoua-DeMarzio D et al. (2023) Am J Med 136(2):200–6 · PMID 36252717 (turmeric liver injury) · Shoba G et al. (1998) Planta Med 64(4):353–6 (piperine bioavailability)
This page is for educational and informational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before beginning any supplement regimen, particularly if you have a history of liver disease, gallbladder disease, take anticoagulant or antiplatelet medications, are pregnant or nursing, or have any medical condition. Discontinue use at least 2 weeks before surgery. If you experience symptoms of liver trouble (jaundice, dark urine, persistent fatigue, right-upper-quadrant pain), discontinue use and seek medical attention.